Basic↦Safety↦Safety Data↦In Clinical Studies
What is it? Why is it important?
In (clinical) studies human volunteers (e.g. healthy persons or patients) are recruited with the aim to add new insight to medical knowledge. Studies can roughly be divided into interventional and observational studies.
The collection of safety data is an essential and critical part, with the aim to:
- Gather safety data in order to protect study participants from unnecessary risks
- Detect relevant safety signals
- Contribute to the ongoing development of the product`s safety profile (e.g. medically relevant information)
- Provide support regarding the risk-benefit assessment of a planned study
The collection of safety data during study conduct / follow-up:
- Starts at the time when the participant signs the ICF, except if otherwise specified in the study protocol
- Ends after the last patient has completed his / her last study visit, or based on a pre-defined follow-up period (e.g. in the study protocol)
What do I need to do?
- Know the laws and regulations that address the safety management of studies (e.g. HRA, GCP, Declaration of Helsinki)
- Based on your study, consult the reference documents that provide up-to-date safety information (e.g. IB for IMP/IMD, instruction for use for MDs, product information for MPs)
- Define how to collect safety data (e.g. safety forms, study database / eCRF)
- Define procedures on how to assess and report safety events during study conduct (e.g. in SOP and WIs)
- Describe safety procedures in your study protocol
- If required, set-up a study safety management plan and establish a Data Safety Monitoring Board (DSMB) (e.g. provides support on safety issues)
- Assess safety data on an ongoing basis during study conduct in order to re-evaluate the risk-benefit ratio of the study (e.g. must remain favourable / benefits must outweigh risks)
More
As a SP-INV manufacturing new IMPs or IMDs:
- Write and regularly up-date the IB section of your product (IMP or IMD), and describe the collected clinical data
Where can I get help?
Your local CTU↧ can support you with experienced staff regarding this topic
Basel, Departement Klinische Forschung, CTU, dkf.unibas.ch
Lugano, Clinical Trials Unit, CTU-EOC, www.ctueoc.ch
Bern, Clinical Trials Unit, CTU, www.ctu.unibe.ch
Geneva, Clinical Research Center, CRC, crc.hug.ch
Lausanne, Clinical Research Center, CRC, www.chuv.ch
St. Gallen, Clinical Trials Unit, CTU, www.kssg.ch
Zürich, Clinical Trials Center, CTC, www.usz.ch
References
ICH GCP E6(R2) – see in particular guideline
- 2 The principles of ICH GCP
ICH - E2A – Clinical safety data management
ICH E8 (R1) – see in particular
- 6.2 Participant safety during study conduct
ISO 14155:2020 Medical device (access liable to costs) – see in particular section
- 4 GCP principles
ISO 20916:2019 In vitro diagnostic medical device (access liable to costs) – see in particular
- Good study practice
Declaration of Helsinki – see in particular
- Risks, Burdens and Benefits
Swiss Law
HRA – see in particular articles
- Art. 4 Primacy of individual interests
- Art. 11-14 Protection of participants
- Art. 15 Safety and protective measures